Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: Secondary analyses of a randomised controlled trial.
Osteoarthr Cartil Open
; 4(2): 100255, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-36475294
ABSTRACT
Objective:
To assess if a change in physical activity occurred after a one-year weight loss period on either liraglutide or placebo in patients with knee osteoarthritis (OA) and overweight.Method:
This is secondary analysis of a one-year weight loss trial, with participants randomised (11) to either liraglutide 3 âmg/day or placebo. The main outcome was change in physical activity (min/day) after one year assessed by accelerometer. Physical function was assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS), function subscale with 100 indicating no disability and 0 indicating extreme disability. Analyses were done on the modified intention to treat population defined as complete baseline accelerometer data.Results:
A total of 135 participants were analysed (66 liraglutide; 69 placebo). Daily physical activity time did not change in either group (liraglutide 15.8 âmin/day; placebo 14.2 âmin/day; mean difference 1.6 âmin/day (95%CI -16 to 19; P â= â0.90)). The liraglutide group lost -4.1 âkg more than placebo (95% CI -6.0 to -2.1; P â< â0.0001) and improved in KOOS function 3.8 points more than placebo (95% CI 0.9 to 6.7; P â= â0.01).Conclusion:
Despite better outcomes on body weight and self-reported physical functioning liraglutide did not induce changes in physical activity over one year in individuals with knee OA.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Osteoarthr Cartil Open
Year:
2022
Document type:
Article
Affiliation country:
Dinamarca